Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CytoDyn Inc announces FDA approval of patient screening for Phase 2b Study with Lead Product Candidate PRO 140 for the Treatment of HIV Type 1


Tuesday, 7 Jan 2014 04:42pm EST 

CytoDyn Inc:Says it has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.Says the Phase 2b study is being conducted by Drexel University College of Medicine and funded by grants from the National Institutes of Health (NIH). 

Company Quote

0.869
-0.0010 -0.11%
11 Jul 2014